投资人提升了制药巨头诺沃·诺迪斯克(Novo Nordisk)的股权,按144.50美元的目标价格评级为“Buy”。 Investors boosted stakes in pharmaceutical giant Novo Nordisk, rated "Buy" with a $144.50 target price.

Blackhawk Capital Partners 和其他公司在第三季度增加了对 Novo Nordisk A/S 的股份，这反映出投资者的兴趣日益浓厚。 Blackhawk Capital Partners and other firms increased their stakes in Novo Nordisk A/S during the third quarter, reflecting growing investor interest. 该制药公司以糖尿病和罕见疾病治疗闻名,其分析师评级混合,目前平均为“Buy”,目标价格为144.50美元。 The pharmaceutical company, known for diabetes and rare disease treatments, has seen a mix of analyst ratings, currently averaging a "Buy" with a target price of $144.50. 诺沃·诺迪斯克的股票在过去一年中在94.73美元至148.15美元之间,市场上限为472.51亿美元。 Novo Nordisk's stock has ranged between $94.73 and $148.15 over the past year, with a market cap of $472.51 billion.